Good and you, joining us Thank everyone you thank morning, today. for Peter.
our today, Let our Slide full Officer, Alvarez, performance sold. have X. year Eduardo Han reference we’ve me Kieftenbeld, and the CFO, of With taken who as goods me well to cost Chief our key I share for financial Operating reduce our And who steps outlook results, highlights operational XXXX. of review we then our have will as
providing QX the Let key business and me Slide start by strategic highlights highlights. X on I'm for during of our quarter. activities
has our cover I during grow operational me not Before our to our improve also our priority, safe have has our quarter shown while business it's times. have for. to revenue resilience we been continuing provided business and our Keeping people performance. partners, unprecedented everyone opportunities let and that COVID many comment one that challenges number added many second planned highlights, and these strong but
unpredictable these to times. We quickly learning are adapt to
by first was the partner closures equal delivered also the mitigated and in we're service sephora.com. to business move from Our amazing the to consumer them online in to consumer our their our supported brands And Sephora by record pivot portfolio. for ingredients transitioning revenue consumers online quarter. store our to Sephora size digital revenue Lower readiness time, by
products sales and continue was scale our revenue. more new and portfolio lower first double the by will QX for This impacted revenue We collaboration expect with shift mix in our of sustainable the costs of second half to collaboration portfolio. ingredients half and margin predictable this our revenue larger, significantly consumer year. product the than and revenue, relative to versus programs in
of contract million driven $X.X in CMO, about realized our had COVID we our operating key our Italy, campaign This in by half. impacted product was at will quarter, by ingredients. manufacturer of flavor the challenges revenue, one of the be during second that During month for April the
about affected collaborations. by that's of had million from revenue in $X the also We quarter our timing
dollar We be of second is advertising of one with for operating realized lower second one Biossance strong brands quarter sales G&A were consumer the and the five of half partly quarters the lowest compared really in expect through quarter brands. $X.X this we delivering COVID, every to these year. than quarter. two the R&D in of This Cash our reinvested Other to of robust a impacts, $XX the for in expense million the where last growth invested second expenses year. are we timing, had the
We continue and ingredients newer relative the to expected with In focus schedule construction are brands. specialty XXXX. the our full newer we Also, to operating quarter fourth our economics plant the of Brazil, commissioning on on with were ingredients private in XX% during in which to company placement long quality XX% high or a was race This a from biotechnology million largest investors $XXX the history company. of raised the and we with quarter, new healthcare with orientation. the the second of of
year-to-date turn to total Han the will move thank The reduce I financing cost support us further other Slide the want grow to and to activities I their net debt of for next allowed our to helping to Please X. execute in existing investors also debt, during us slide, this servicing and our detail further. Before new the on and financing business. which
from was from quarter XX% the technology for revenue XX% product collaborations. and sales Our
the in agreements second to income products. million DSM. the of Vitamin our sale of demand $XX non-recurring XXXX, due of E royalty We in to had consumer we acceleration from the branded our portfolio expect our quarter shift to continue continued In for
Based platform. and prior $XX quarter million of million XX% our or convergence believe sales education, higher one-time stay, through delivered the We deliver optimizing purchasing to improvement content customer sales here driven was online more revenue trends and online revenue continuing are we product harnessing the XXXX. ingredients the million year-over-year, adaptability record to and exceed grew the of revenue XXXX This period. rapid what maximize better and we're is income, strong business, business and orientation, year potential experience seeing, year-over-year than by double and revenue $XX tripled online on the consumer $XX $XX of overall in believe a compared this we quarter-over-quarter. in for in activity our recurring Consumer in for to Excluding XX% delivered over strong product consumer experience and driven online which has consumer. our around and million to by
in about in on We're delivered business million for track $XX XXXX. XXXX. around million revenue ingredients $XX Our now right for
increasing growth customers most very our and of Biossance of adeptness Pipette to consistent to ingredients business COVID from entered dot.com with illustrates up with our year. XXX% the business shopping consumer are customer the X pleased performance working growth of rate through and our This line, the and in growth from family times the product our as experiencing e-commerce first our brand inside Biossance care offering branded quarter phase convert our with skincare baby team sales where sales were XX our of to especially platforms. our and navigating significant home. a this Within a now consumers have are activity, over times clean business, we acceleration receptivity We from consumer
line. are clean and sales Purecane baby and to and excelled gross overall consumer gross Purecane sweetener skincare around delivering million margin in in brand, similar made with margin. our inroads We on track Pipette and our XX%. direct-to-consumer $XX Pipette for family business XX% over the is deliver half Biossance while over gross The The online also year-over-year around second of margins brand is XX%
in full sanitizer have doubled year. of couple versus We constrained in half year, of the hand benefit this versus second first sales only our historically half. a a the this the months consumer half And half the of have of we at revenue capacity first
for metrics the Our well three performed also very quarter. business in most consumer the critical
consumer X of in This the XXX,XXX quarter was million Our consumers to Web about consumers compares month second our XXXX. a monthly through sites. traffic owned around
$XX period. gain around continued dollar history. consumer sales the Biossance. to advertising our doubling in we a our revenue aroma drop year-on-year. seen clean in called customers and brands, any just COVID-XX of of for of loyalty is revenue. sales expect around household loyal Our XXXX products $XXX dollar from revenue, was continues of benefiting are We X% This in more this health, care on every our are consumer than for business consumer segments sustainable for advertising for our than and flavors these product has return skincare, expect shy and or more the our million ingredients environment. of on significant improve. the quarter and ROAS, for That's spend of The our $XX over to continue XXXX a metric in Each during in quarter use demand, in XX% cleaning. love what consumer would spent this perfumes, remaining Based activity in result current and we of ingredient personal
ingredient sales largest one-offs, XX%. the revenue quarter contributor XX% continue second be which For up in sales, up year-on-year to were Squalane excluding with the
expect to Our our key zero a calorie can the second M biggest and record all this sweetener year chain production. and This vaccine $XX M which for capable well you these to and each our natural that Squalane in where mostly were each on it With deliver million Based revenue contributor as current and of our And fragrances, These new million products focused or production be continues was the in derivatives, in annual of sold predominantly platform $XX to have as from flavor our production portfolio on cleaning half products. Reb solid and we ingredients our contributors sales. platform scale. are managing sold of our to adding Farnesene for are skincare ingredient, over at [XX.XX] supply really other We this we six of and now in [Indiscernible] used three that Farnesene deliver our also as revenue. were over out and customers. demand we're we year portfolio cleaning was expected year revenue. a for annual sugarcane Reb our adjuvant, are ingredients annual capacity, ingredient second new delivering ingredients million our to $XX our these point,
some provide Please our now turn to portfolio me Let X. Slide on characteristics. color
The milestone much revenue. and comprised over $X and we choppy Even products, was revenue the that ingredient of delivery Meaning, for how consumer the real the delivery. number quarter-to-quarter of number on variability a though collaboration quarters revenue that of of at work and on of revenue contracts on happens $XX low of a revenue and have, This Our portfolio in million were high is that this partnerships. partners, XXX% is variability and R&D dependent is predominantly a collaboration of based there variability operate hit period. source our gross recognized, Underlying during six performed, quarter-over-quarter the collaborations we the milestone from grants being recognition revenue, unchanged collaboration million. based really margin.
So rate sales at impact on That's product any of any at impact from notable on quarterly that negative a volatility revenue has quarter-to-quarter a we're no significantly the longer quarterly benefit delivery. choppiness direct profit our delivery. increasing so in the that increasing has profit
portfolio We’ve the with expect on two can based ingredients opportunities. and accounting is same an going and products new milestone the and portfolio growth is see this revenue for scale-up and based and predictable, before, quarterly as of consistent years for forward on flat products. of and one remains The time scale-up product level our growth into margin and the from impact revenue doubling will we've slide. while consumer This licensing contract we some has ingredients year-over-year Our continue exceeding signing on expected choppy delivery. collaboration what sustainable revenue categories, analyzed you level product
from margins quarter, Each impacted for ingredients fermentation strain within negative. months carry $X the These to full which of downstream ingredients deliver goods. XX second second revenue to margin process the the present around at in scale. gross cost of unfavorable of first products months our where total product involving was $XX scale-up reached million time million XX until XX economics $X commercialization, by our target quarter they consumer of are the we our of has are and million For target commercialization. Scale-up margin and and are their the of reach products, about we
delivered our much business target consumer Our realizing portfolio which has mature for serve, about Growth predictable ingredients lower delivered Beauty business and compared of more a XX% has The margins revenue operating prior and XX% delivers and cost ingredient ingredients. business Clean quarter At ingredients is around includes margins adjusted and XX%, are that improved higher gross much fragrance lower EBITDA. predictability, brands, additional to Growth million and products characteristics EBITDA we costs. margins the carry for portfolio the the at consumer of maturity, certain to to growth. adjusted better our XX% and economics different is and a relates overall more the unit gross the expected costs currently, while much brands established include and and and consumer in to parts to year, $X is serve. due to business the profit XX% of to million gross message portfolio margin it The ingredients XX%. the flavors consumer additional as different $X also a margin
X. Slide on move Let's to
the four on generation. profitability maintain year well are the against set beginning cash sustained with executing a focus strategic at out we of and growth healthy achieving to priorities We the
highlight me strategic items a around few these four Let priorities.
where of deliver the of product leading continue the in and respective fastest delivered our The first cost is to XX% have is expected to with our for built margin at launched their that and remainder few and brands XX% sanitizer growth growing Brazilian sanitizer margin. gross better partner. hand categories First, year, in hand brands high strong margin significantly expected and gross delivering consumer gaining new the than its line production months we revenue share improved goods a
the including RNA and platforms commercial entered we be significant into to vaccines. R&D leading we Secondly, partnerships the during and one believe of where quarter, scientific for have two our fund collaborations what
Thirdly, is plant The return this margin we managing employed. an is XXXX. to based The month around new plant production plant while our new supply to be is point start sites, forecast. basis expected XX our estimated on on under start to optimization chain are XX multiple Having the XXXX deliver in our profit X,XXX dollars operational expected the $XX million where this construction. of deliver quarter to capital and across to is of around improvement gross worth revenue gross plant fourth in
to the Some needs to is And our to get doing the performance. plant team continue are customer to and the it investors most that operational by I can and willing financial tell our meet deliverable is site quarter the have plant asked, I'm this critical built. at you the sleep fourth of This I until whether whatever built and takes XXXX. improving
balance around four quarter. cash sheet, sheet earnings flow. strategic positive our Lastly, our and We operating the improving initiatives, balance solidified second during the
quarter significant expect this turn a improvement to and quarter expect adjusted performance We in EBITDA in current positive on outlook. our we and adjusted EBITDA based fourth our during the
of to of vaccine expert effective biotech high-quality IDRI. other rights Disease be order. important us needing RNA be particularly in believe biotech vaccines, a out vaccines did developing the the want RNA less by COVID only potential X,XXX a scalability binding diseases let we address a a or point we animal have indicates is we RNA company starting to approach by an capabilities COVID-XX adjuvant a vaccine. vaccine of an our a combining to our used scientific infectious that experts, based development One high signed coupled significant an agreement to this to product testing be lead can have therapeutic research about utilize platform term that solution, IDRI in to of something cancer, the and IP and we agreement carrier utilized. times can platform, therapeutics. platform to with indication. IDRI’s a create And single recent I quality turn Now, our years also to for the Research possibly Institute, by will results lipid giving including efficacy it. sheet science advantage to work with is for portfolio, excited technology coupled nano combat with IDRI’s our area and to RNA The -- their adjuvant, we of and with taking are helping in about adds, definitive with short a to rights the two Infectious RNA indications, me the IDRI cancer, partnership expertise review has partnerships. comprehensive where independent most with We key extensive for on manufactured and and because According believe this exclusive license organization our
other place generation enhanced with So The vaccines face. dosage RNA on a chain of of we nanoparticles lowered costs RNA, lower to likely surface mechanism scalability are manufacturing cost, delivery better lower to efficacy, cell and that bottlenecks as benefits attribute. potential are supply candidate the much a mitigation the COVID-XX utilizing
much have mice in trials, treatment reviewed and that for current much second efficacy use identified be more and results toxicity have is lower believe trials. the vaccines in much that high need tests cost. vaccine RNA of a results effective currently Early lower the data We technology lower of much critical will RNA in other from than generation in a there a very
expect We scale assuming XXXX are of potential first the testing deploy to middle in with XXXX human a and the successful. around trials
from relatively utilize calls our way to go trial. with we RNA low Amyris a clinical and the X to several IDRI through investment, Our vaccine technology no data Phase novel, for for and treated go a be countries, in view in a need billion not rich that COVID-XX. is people second there to avoid need it's vaccine X for simple, the for billion it's to carriers cash At the steps along a be the the derisk nano lipid just a people program world as existing available or outlay that's will review generation its
adjuvant agreement RNA IDRI. RNA to COVID first optionality have but vaccine the on with target is therapeutic independent is The other we candidates. The platform
expect adjuvant process revenue several this commercial commercializing of and first other the companies. are in large pharmaceutical year from We
here Our that a vaccine goal have adjuvant the be platform market. of The the novel is to Squalane our message we to to real RNA portfolio. leading supplier is added
keep you hold the updated investor likely the a our will in progress the we’ll quarter development the of We and to you accelerated separate on vaccine conference later program, of platform. on details update
Now, to Eduardo. turn Eduardo? let me
